138 related articles for article (PubMed ID: 11911422)
21. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
[TBL] [Abstract][Full Text] [Related]
22. T-cell prolymphocytic leukemia with hemorrhagic gastrointestinal involvement and a new chromosomal abnormality.
Toyota S; Nakamura N; Dan K
Int J Hematol; 2002 Apr; 75(3):314-7. PubMed ID: 11999363
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
24. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
25. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
26. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
27. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
Hertenstein B; Wagner B; Bunjes D; Duncker C; Raghavachar A; Arnold R; Heimpel H; Schrezenmeier H
Blood; 1995 Aug; 86(4):1487-92. PubMed ID: 7632956
[TBL] [Abstract][Full Text] [Related]
28. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.
Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJ; Catovsky D; Mellstedt H
Br J Haematol; 1996 Apr; 93(1):151-3. PubMed ID: 8611450
[TBL] [Abstract][Full Text] [Related]
29. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.
Geissinger E; Bonzheim I; Roth S; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Leuk Lymphoma; 2009 Jun; 50(6):1010-6. PubMed ID: 19479612
[TBL] [Abstract][Full Text] [Related]
30. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?
Delgado J; Bustos JG; Jimenez MC; Quevedo E; Hernandez-Navarro F
Leuk Lymphoma; 2002 Dec; 43(12):2331-4. PubMed ID: 12613520
[TBL] [Abstract][Full Text] [Related]
31. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
32. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
33. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
34. [Immunophenotype of chronic lymphocytic leukemia and prolymphocytic leukemia].
Maruyama S
Nihon Rinsho; 1992 Jun; 50(6):1236-40. PubMed ID: 1518139
[TBL] [Abstract][Full Text] [Related]
35. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia.
Kojima K; Kobayashi H; Imoto S; Nakagawa T; Matsui T; Kawachi Y; Oda K; Yano T; Kobayashi H; Noguchi M; Hara M; Oshimi K
Int J Hematol; 1998 Oct; 68(3):291-6. PubMed ID: 9846013
[TBL] [Abstract][Full Text] [Related]
36. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
37. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
39. Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.
Ogasawara T; Narita C; Kawauchi K
Leuk Res; 2007 Mar; 31(3):403-6. PubMed ID: 16620970
[TBL] [Abstract][Full Text] [Related]
40. Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
Foucar K
Am J Clin Pathol; 2007 Apr; 127(4):496-510. PubMed ID: 17369126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
